Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 294 of 5804
-
Half-Dose malaria vaccine could double protection for millions
⭐️ VACCINE ⭐️ Not yet recruitingThis is a single blind randomised controlled trial (Phase 3 trial). This study aims to assess whether a half-dose of the R21/Matrix-M malaria vaccine is as effective as the full dose in children and adults. The results will help optimize vaccine usage and improve malaria preventi…
Phase: PHASE4 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 11:01 UTC
-
Starving liver tumors: new combo aims to stop cancer from eating itself
Disease control Recruiting nowTrans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC). TACE is a minimally invasive procedure that involves placing a catheter into the artery in the liver that feeds the tumor, administering chemot…
Phase: PHASE1, PHASE2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can blood transfusions protect pregnant women with sickle cell disease?
Disease control Recruiting nowThe goal of this study is to determine if there is a positive effect of prophylactic red blood cell (RBC) transfusion of leukoreduced, ABO, Rh (D/Cc/Ee) and Kell matched blood compared to standard of care on the number of episodes of acute sickle cell disease (SCD) manifestations…
Phase: PHASE4 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Experimental drug aims to boost immune attack on aggressive brain tumors
Disease control Recruiting nowThis phase II trial compares the effect of GI-102 alone and in combination with pembrolizumab given before surgery in treating patients with IDH wildtype glioblastoma and IDH mutated grade 4 astrocytoma that has come back after a period of improvement (recurrent) or that is growi…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo therapy aims to tackle lung cancer brain metastases
Disease control Not yet recruitingPatients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with brain metastases remain a major clinical challenge. Although EGFR-TKIs have demonstrated intracranial activity, disease control is still suboptimal in some patients. Limertinib (…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug combo aims to tame rare artery disease
Disease control Not yet recruitingThis is a prospective, open-label, controlled, multiple centers, randonmized clinical trial. It compares the clinical efficacy and safety of vunakizumab ivarmacitinib and glucocorticoids in the treatment of active Takayasu's arteritis.
Phase: PHASE4 • Sponsor: Chinese SLE Treatment And Research Group • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Off-the-Shelf CAR-T cells take on tough leukemia in early trial
Disease control Recruiting nowThis study is a single arm, open label, dose exploring clinical trial to evaluate the safety, efficacy, cellular metabolic dynamics, and pharmacodynamics of ct1190b cells in relapsed / refractory B-cell acute lymphoblastic leukemia.
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Magic mushroom compound may ease despair in advanced cancer patients
Symptom relief Recruiting nowDemoralization syndrome is frequently present in palliative care and oncology patients. In particular, up to a third of patients diagnosed with cancer will experience demoralization due to their illness. The relevance of demoralization syndrome in oncology is tied to this syndrom…
Phase: PHASE1 • Sponsor: Gustavo Vazquez • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
New hope for Drug-Resistant leukemia: phase 3 trial launches
Disease control Not yet recruitingA Phase III study evaluating the safety and efficacy of TGRX-678 in CML-CP patients resistant from or intolerant to at least 3 TKIs
Phase: PHASE3 • Sponsor: Shenzhen TargetRx Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
AI eye on X-Rays: could a computer save lives in the ER?
Diagnosis Not yet recruitingBackground Advancements in artificial intelligence (AI) have driven significant breakthroughs in computer-aided detection (CAD) for chest X-ray imaging. National Taiwan University Hospital (NTUH) research team previously developed an AI-based emergency Capstone CXR system (MOST 1…
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 11:03 UTC
-
Poop pills join the fight against advanced colon cancer
Disease control Not yet recruitingThis clinical trial evaluates the efficacy and safety of adding fecal microbiota transplantation (FMT) to first-line standard of care for patients with initially unresectable colorectal cancer (CRC). FMT is an established procedure designed to restore intestinal microbiome homeo…
Phase: PHASE2, PHASE3 • Sponsor: Shanghai 10th People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New trial tests whether education can shield teens from exploitation
Prevention Not yet recruitingAlthough the exact scope of commercial sexual exploitation of children (CSEC) remains unknown, its significant negative physical and emotional consequences for children has been well-documented. The U.S. government recognized the need for improved CSEC prevention over two decades…
Phase: NA • Sponsor: University of New Hampshire • Aim: Prevention
Last updated Jun 27, 2026 12:01 UTC
-
Could a tongue swab replace sputum tests for TB?
Diagnosis Not yet recruitingTuberculosis (TB) remains the leading cause of death from a single infectious agent globally, with millions of people still undiagnosed or diagnosed late. Conventional case-finding strategies rely heavily on symptom screening using the WHO Four-Symptom Screen ((W4SS; comprising a…
Phase: NA • Sponsor: Liverpool School of Tropical Medicine • Aim: Diagnosis
Last updated Jun 27, 2026 12:05 UTC
-
New vaccine aims to fight Hard-to-Treat EBV cancers
Disease control Not yet recruitingEpstein-Barr virus (EBV) is a double-stranded DNA virus belonging to the Gammaherpesvirinae subfamily of Herpesviridae. It primarily infects B cells and pharyngeal epithelial cells, and can also infect NK cells and T cells. EBV is closely associated with a variety of hematologica…
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New shot could help eczema sufferers who Don't respond to steroids
Disease control Not yet recruitingThe main aim of the study is to evaluate the efficacy, safety, and tolerability of lebrikizumab treatment in adult participants with Nummular Eczema (NE) who are not adequately controlled with Topical corticosteroids (TCS) or when this treatment is not medically advisable.
Phase: PHASE3 • Sponsor: Almirall, S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for tough stomach cancer: triple drug attack
Disease control Not yet recruitingThe goal of this clinical trial is to learn if the combination of disitamab vedotin, tunlametinib, and a PD-1 antibody works to treat HER2-overexpressing advanced gastric cancer in patients who have already received at least two lines of prior therapy. It will also learn about th…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Smartwatches may help doctors decide when to treat AF, new trial aims to prove it
Disease control Not yet recruitingTraditional AF classification (e.g., paroxysmal, persistent, permanent) relies largely on patient-reported symptoms and intermittent electrocardiographic monitoring, which cannot continuously or objectively reflect disease progression, nor effectively inform optimal intervention …
Phase: NA • Sponsor: Navy General Hospital, Beijing • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New combo shows promise for Tough-to-Treat leukemia
Disease control ENROLLING_BY_INVITATIONThis study aims to evaluate the safety and efficacy of homoharringtonine combined with venetoclax and azacitidine regimen (HVA) in newly diagnosed MPAL patients, providing a basis for the use of the HVA regimen in the treatment of MPAL.
Phase: PHASE2 • Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Promising combo tackles Hard-to-Treat breast cancer
Disease control Recruiting nowThe UNITY study is a prospective, single-arm, single-center, Phase II clinical trial conducted by Fudan University Shanghai Cancer Center. It aims to evaluate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) combined with ivonescimab in patients with hormone receptor-pos…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Intensive PTSD therapy shows promise for rapid symptom relief in special operations troops
Disease control Recruiting nowOur long-term goal is to provide rapid and sustained reductions of trauma and cognitive-related symptoms among Special Operations personnel with PTSD or subthreshold PTSD. The primary objective of this project is to examine the effectiveness of massed PTSD treatment (i.e., CPT an…
Phase: NA • Sponsor: Ohio State University • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC